A study on respiratory syncytial virus (RSV) suggests that mucosal IgA against the pre-fusion F protein predicts protection, offering actionable evidence for immunogenicity targeting in vaccine and antibody programs. For developers, correlates of protection can sharpen candidate selection and trial design. Separately, Space Pharmaceuticals reported patents for cationic antimicrobial peptides covering use across inflammatory disorders and broad-spectrum infectious indications. These disclosures and immunology correlates reinforce continued platform-style development across both vaccines and next-generation antimicrobials.